CV Sciences, Inc.

Legislation delays implementation of new federal hemp restrictions until December 11, 2026, preserving continued access to naturally derived hemp products Legislation delays implementation of new federal hemp restrictions until December 11, 2026, preserving continued access to naturally derived hemp products SAN DIEGO, CA / ACCESS Newswire / September 8, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today welcomed the enactment of federal legislation that delays implementation of significant changes to the federal definition of hemp and provides additional time for Congress and the Administration to develop a comprehensive regulatory framework for hemp-derived cannabinoid products. The legislation passed the U.S. House of Representatives by a bipartisan vote of 370-48 and the Senate by a vote of 90-6, President Trump signed the legislation into law on September 1. The new law delays implementation of federal hemp restrictions from November 12, 2026 to December 11, 2026. This extension gives Congress additional time to determine the future regulatory framework governing hemp-derived products while preserving continued access to qualifying naturally derived hemp products during the extension period. CV Sciences believes the additional time provided by the legislation represents an important opportunity to establish clear, consistent and science-based federal standards that protect consumers while preserving access to responsibly manufactured hemp-derived wellness products. "We welcome the enactment of this legislation and the additional time it provides for Congress to get the regulatory framework right," said Joseph Dowling, Chief Executive Officer of CV Sciences. "CV Sciences has been committed to quality, transparency and responsible hemp-derived CBD products for more than a decade. We believe consumers deserve access to products that are manufactured to rigorous standards, accurately labeled and supported by appropriate testing. At the same time, we believe the industry needs clear and consistent rules that distinguish responsibly manufactured, naturally derived hemp products from products that raise legitimate safety and regulatory concerns." The Company believes that responsible federal regulation can provide greater certainty for consumers, retailers, manufacturers and farmers while establishing appropriate standards for product quality, manufacturing, testing, labeling and marketing. A More Sustainable Regulatory Framework The federal legislation provides a temporary extension, rather than a permanent resolution of the regulatory issues facing the hemp industry. CV Sciences believes the additional time should be used to develop a durable framework that recognizes the distinction between naturally derived hemp products and synthetic or otherwise inappropriate cannabinoid products. "This legislation is an important step, but it should be viewed as an opportunity rather than an endpoint," added Joseph Dowling. "We encourage policymakers to use this additional time to establish sensible, enforceable standards that protect consumers and responsible businesses alike. A clear federal framework would provide greater confidence throughout the supply chain and allow companies like CV Sciences to continue investing in quality, innovation and consumer education." CV Sciences supports regulatory standards designed to promote responsible manufacturing and marketing of hemp-derived products, including appropriate product testing, accurate labeling, quality-control requirements and transparency for consumers. The Company will co

SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 and Recent Financial, Operating and Regulatory Highlights Generated revenue of $3.0 million for the second quarter 2026 compared to $3.6 million for the second quarter 2025 and compared to $3.2 million for the first quarter 2026; Recognized gross margin of 48.6% for the second quarter 2026 compared to 50.9% for the second quarter 2025 and compared to 48.9% for the first quarter 2026; Cash balance of $0.3 million at quarter and year end; Reduced operating expenses by 11.3% to $1.7 million for the second quarter 2026 compared to $2.0 million for the second quarter 2025, and by 6.9% from $1.9 million in the first quarter 2026; Recognized an adjusted EBITDA loss of $0.1 million for the second quarter 2026 compared to positive adjusted EBITDA of $0.1 million for second quarter 2025 and compared to an adjusted EBITDA loss of $0.1 million for the first quarter 2026; Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging; Launched PlusHLTH.com, a new dedicated e-commerce platform strengthens the Company's strategy to build a leading science-backed health and wellness portfolio; and U.S. Senate voted 61-32 to approve Continuing Resolution H.R. 6500, which delays the implementation of restrictive provisions for hemp-derived cannabinoid products, allowing valuable time to develop a longer-term solution and sensible regulatory framework for hemp-derived products. "Our second quarter results reflect continued disciplined execution despite a challenging regulatory and consumer environment. While revenue remained under pressure, we maintained healthy gross margins, further reduced operating expenses, and continued to strengthen the financial foundation of the business. We believe these actions position us to improve profitability and generate positive cash flow as market conditions normalize," stated Joseph Dowling, Chief Executive Officer of CV Sciences. "During the quarter, we also expanded our +PlusHLTH™ portfolio with personalized wellness solutions designed to support healthy aging, further advancing our strategy to diversify beyond cannabinoids into broader science-based wellness categories. Looking ahead, we remain focused on disciplined capital allocation, operational excellence, and selectively pursuing strategic opportunities that strengthen our brands and create long-term shareholder value." Operating Results - Second Quarter 2026 Compared to Second Quarter 2025 Sales for the second quarter 2026 were $3.0 million, a decrease of 17.5% from $3.6 million in the second quarter 2025. The decline is driven by lower sales volume due to restrictive regulations at the federal level and in certain states. The total number of units sold during the second quarter 2026 decreased by 14.9% compared to the second quarter of 2025. We also realized some minor decreases in average sales prices. In addition, 44% of our net revenue for the second quarter 2026 was from new products launched since January 1, 2023. During this time period, we launched 52 new products. We generated an operating loss of $0.3 million in the second quarter 2026, compared to an operating loss of f $0.1 million in the second quarter 2025. The change is mostly due to lower sales and associated gross profit, partially offset by reduced operating expenses. We had negative adjusted EBITDA of $0.1 million

New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging. SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "our", "us" or "we"), a consumer health company specializing in science-backed natural ingredients and products, today announced the launch of PlusHLTH.com, a new direct-to-consumer destination dedicated exclusively to the Company's growing +PlusHLTH™ product line. The launch of PlusHLTH.com represents an important milestone in the Company's long-term strategy to expand beyond cannabinoids and establish +PlusHLTH™ as a leading brand focused on healthy aging, performance, and everyday health. The new site creates a distinct home for +PlusHLTH™, while PlusCBDOil.com remains focused on the Company's industry-leading hemp-derived CBD portfolio. Built around CV Sciences' Health Intelligence approach, PlusHLTH.com is designed to be more than an e-commerce destination. The site brings together science-backed products and educational content to help consumers better understand their changing needs, explore targeted solutions, and make more informed decisions as they age. "Our launch of PlusHLTH.com marks an exciting step in the evolution of CV Sciences," said Joseph Dowling, Chief Executive Officer of CV Sciences. "For more than a decade, we have earned the trust of consumers through our commitment to quality, scientific research, and product innovation with the PlusCBD brand. +PlusHLTH™ builds on that foundation by bringing the same commitment to a broader range of solutions designed to support healthy aging, active lifestyles, and everyday health." "PlusHLTH.com gives +PlusHLTH™ its own distinct digital identity and creates a stronger connection with consumers," Dowling continued. "As the brand grows, the site gives us a place to introduce new products, provide meaningful education, and create an experience that evolves alongside our customers." +PlusHLTH™ currently offers a growing range of non-cannabinoid nutritional products, including targeted dietary supplements in capsule and gummy formulations and Empowr, the Company's plant-based protein with creatine. The Company plans to continue expanding the line with new formulations and delivery formats designed to address evolving consumer needs. PlusHLTH.com will serve as the primary digital home for +PlusHLTH™ products, education, new product introductions, and future innovation as CV Sciences continues to expand its presence in the broader health and nutrition market. Consumers can explore the new website and learn more about +PlusHLTH™ by visiting www.PlusHLTH.com. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company focused on developing and commercializing science-backed natural products that support health and well-being. Through its trusted consumer brands, the Company offers a broad portfolio of premium hemp-derived CBD products, non-cannabinoid dietary supplements, and plant-based nutrition products designed to help consumers optimize their health at every stage of life. The Company's +PlusCBD™ brand is among the leading hemp-extract brands in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic, and specialty products industry. +PlusCBD™ was the first hemp extract supplement brand to achieve self-affirmed Generally Recognized as Safe (GRAS) status and is supported by human clinical research and pub

SAN DIEGO, CA / ACCESS Newswire / August 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2026, after the stock market closes on Thursday, August 13, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1769578&tp_key=ae0ce79bc9. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, August 20, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13761707. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature

SAN DIEGO, CA / ACCESS Newswire / May 14, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2026. First Quarter 2026 and Recent Financial and Operating Highlights Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025 and compared to $3.3 million for the fourth quarter 2025; Recognized gross margin of 48.9% for the first quarter 2026 compared to 46.0% for the first quarter 2025 and compared to 50.5% for the fourth quarter 2025; Cash balance of $0.3 million at quarter and year end; Reduced operating expenses by 13.3% to $1.9 million for the first quarter 2026 compared to $2.2 million for the first quarter 2025, excluding benefit from reversal of accrued payroll taxes; Recognized an adjusted EBITDA loss of $0.1 million for the first quarter 2026 compared to $0.3 million for first quarter 2025 and compared to positive adjusted EBITDA of $0.1 million for the fourth quarter 2025; Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness, and Completed successful debt restructuring designed to strengthen financial position and fuel future growth. "We are pleased with our first quarter 2026 results, which reflects continued progress in strengthening our operational and financial foundation," stated Joseph Dowling, Chief Executive Officer of CV Sciences. "Our gross margins remained strong during the quarter, and we expect additional improvement in the second half of 2026 as we continue optimizing our product mix and operating structure. We remain focused on disciplined expense management, operational efficiency, and driving the business toward sustainable profitability and positive cash flow." "During the quarter, we also completed a successful debt restructuring that improved our financial flexibility and positions us to pursue strategic growth initiatives more effectively. At the same time, we believe the current market environment presents attractive opportunities to accelerate growth through strategic acquisitions that complement our existing brands and leverage our operational platform. We are committed to pursuing opportunities selectively and with financial discipline, while continuing to focus on long-term value creation for our shareholders." Operating Results - First Quarter 2026 Compared to First Quarter 2025 Sales for the first quarter 2026 were $3.2 million, a decrease of 11.4% from $3.6 million in the first quarter 2025. The decline is driven by lower sales volume due to restrictive regulations at the federal level and in certain states. The total number of units sold during the first quarter 2026 decreased by 12.2%, partially offset by minor increases in average sales prices. In addition, 43% of our net revenue for the first quarter 2026 was from new products launched since January 1, 2023. During this time period, we launched 45 new products. We generated an operating loss of $0.3 million in the first quarter 2026, compared to operating income of $11,000 in the first quarter 2025. The change is mostly due to the reversal of accrued payroll taxes of $0.5 million in the first quarter 2025, offset by reduced operating expenses. We had negative adjusted EBITDA of $0.1 million for the first quarter 2026 compared to $0.3 million in the first quarter 2025. The improvement is mostly due to lower operating expenses. Conference Call and Webcast The Company will host a conference cal

SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2026, after the stock market closes on Thursday, May 14, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1760203&amp;tp_key=9a8cb9d283. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, May 21, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13760149. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.<br /

SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for the third quarter 2025; Recognized gross margin of 49.0% for fiscal 2025, a significant improvement from 45.6% for 2024; Gross margin of 50.5% for the fourth quarter 2025 compared to 43.2% for the fourth quarter 2024 and 48.5% for the third quarter 2025; Cash balance of $0.3 million at year end compared to $0.5 million at the end of 2024; Reduced operating expenses by 17.2% to $7.7 million for fiscal 2025 compared to $9.4 million for 2024, excluding benefit from reversal of accrued payroll taxes; Recognized an adjusted EBITDA loss of $0.3 million for fiscal 2025 compared to $0.8 million for 2024; Recognized positive adjusted EBITDA of $0.1 million for the fourth quarter 2025, significantly improved from adjusted EBITDA losses of $0.4 million for the fourth quarter 2024 and $0.1 million for the third quarter 2025; Expanded +PlusCBD™ product offering with the launch of Ignite, a men's performance formula for vitality, recovery, libido and focus (Q3 2025); and Launched EMPOWR, a plant-based protein and creatine formula designed for total wellness (Q1 2026), and Completed successful debt restructuring designed to strengthen financial position and fuel future growth (Q1 2026). "We made meaningful progress in 2025 executing against our top priorities of improving margins, reducing our cost structure, and moving the business toward sustainable profitability. Our gross margin expansion and significant reduction in operating expenses drove a substantial improvement in adjusted EBITDA, culminating in positive adjusted EBITDA in the fourth quarter," stated Joseph Dowling, Chief Executive Officer of CV Sciences. "As we enter 2026, we are building on this momentum by further enhancing operating efficiency and driving consistent positive cash flow. At the same time, we see a compelling opportunity to accelerate growth through disciplined, strategic acquisitions that complement our existing portfolio and leverage our operational platform. We believe this balanced approach-combining near-term profitability with targeted M&amp;A-positions CV Sciences to deliver improved financial performance and long-term shareholder value." Operating Results - Full Year 2025 Compared to Full Year 2024 Sales for fiscal 2025 were $13.8 million, a decrease of 12.2% from $15.7 million in 2024. The decline is driven by lower sales volume due to temporary out-of-stock issues for some of our key products and restrictive regulations at the federal level and in certain states. The total number of units sold during fiscal 2025 decreased by 12.6%, partially offset by minor increases in average sales prices. In addition, 39% of our net revenue for the year ended December 31, 2025 was from new products launched since January 1, 2023. During this time period, we launched 39 new products. We generated an operating loss of $0.5 million in fiscal 2025 significantly reduced from $2.2 million in 2024. The lower operating loss is mostly due to reduced operating expenses across the business. We had negative adjusted EBITDA of $0.3 million for fiscal 2025, als

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year end and fourth quarter ended December 31, 2025, after the stock market closes on Thursday, March 26, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day. The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1754173&amp;tp_key=c94416da11. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, April 2, 2026, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13759006. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com. FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by t

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share. "We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant milestone in the Company's strategic plan to enhance financial flexibility and accelerate long-term growth," said Joseph Dowling, CEO of CV Sciences. "This is a transformative step for our Company in strengthening our balance sheet and positioning the Company for sustained profitability. This transaction better equips us to deliver value to our customers, partners and shareholders, while pursuing new opportunities with confidence." CV Sciences has recently launched Empowr, a plant-based protein and creatine formula designed for total wellness. With this launch, CV Sciences has continued to expand its growing portfolio of innovative wellness solutions under its +PlusHLTH™, Happy Living Through Health, cannabinoid-free supplement line. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the +PlusHLTH line delivers targeted formulations for optimized health, improved performance, and increased vitality. For more information, please visit https://www.pluscbdoil.com/plushlth.html or https://www.cvsciences.com/. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CV Sciences, Inc. CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ subsidiary specializes in contract manufacturing and branded products for the nutraceutical and plant-based food industries, with distribution primarily across the EU and select international markets. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by vis